Search

OFFICE ASSISTANT - INOVIO PHARMACEUTICALS - SAN DIEGO, CA

Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that...

Bio Roundup: Nationwide's Rise, a Surgeon's Quest, CRISPR USA & More

BIO ROUNDUP: NATIONWIDE'S RISE, A SURGEON'S QUEST, CRISPR USA & MORE

Persistence and perseverance were the themes of two of our top stories this week. First there's the story of Nationwide Children's...

 
 
 
Probiotics may be good for your gut but bad for your immune system, study suggests

PROBIOTICS MAY BE GOOD FOR YOUR GUT BUT BAD FOR YOUR IMMUNE SYSTEM, STUDY SUGGESTS

Taking probiotics may actually make the gut microbiome less diverse, and in turn prevent immunotherapy from fighting cancer, new research...

 
 
 
Immunotherapy drug which could stall lung cancer for up to five years will now be funded by the NHS 

IMMUNOTHERAPY DRUG WHICH COULD STALL LUNG CANCER FOR UP TO FIVE YEARS WILL NOW BE FUNDED BY THE NHS 

The injectable cancer drug Imfinzi, pharmaceutical name durvalumab, will be available on the NHS from today in what has been called...

FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

 
 
 
Bio Roundup: Golumbeski's Legacy, CRISPR Moratorium, Rebate Week & More

BIO ROUNDUP: GOLUMBESKI'S LEGACY, CRISPR MORATORIUM, REBATE WEEK & MORE

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb's proposal to buy Celgene for $74 billion...

Gene Therapy Boom, Cracking Alzheimer's: What's Hot on May 21

GENE THERAPY BOOM, CRACKING ALZHEIMER'S: WHAT'S HOT ON MAY 21

Our annual half-day life sciences variety show, “ What's Hot in Biotech ,” is back. Join Xconomy on May 21 at Bristol-Myers Squibb's...

 
 
 
Roche's Tecentriq approved as first immunotherapy drug for breast cancer

ROCHE'S TECENTRIQ APPROVED AS FIRST IMMUNOTHERAPY DRUG FOR BREAST CANCER

The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive...

 
 
 
Anti-cancer Immunotherapy to Fight Persistent HIV

ANTI-CANCER IMMUNOTHERAPY TO FIGHT PERSISTENT HIV

CRCHUM researchers are exploring a potential therapeutic approach for treating HIV patients with persistent virus

DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead

DBV REJOINS PEANUT ALLERGY TREATMENT RACE, BUT AIMMUNE TAKES THE LEAD

DBV Technologies is jumping back into the race to bring an FDA-approved peanut allergy treatment to the market, but it might not be...

 
 
 
Harpoon's IPO Spears $76M as Prostate Cancer Drug Continues Testing

HARPOON'S IPO SPEARS $76M AS PROSTATE CANCER DRUG CONTINUES TESTING

Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets, raising approximately $76 million...

Bolt Bio Bags $54M for Drugs that Turn the Heat Up on “Cold” Tumors

BOLT BIO BAGS $54M FOR DRUGS THAT TURN THE HEAT UP ON “COLD” TUMORS

In cancer lingo, “cold” tumors are cancers that the immune system doesn't recognize or respond to, even when immune-stimulating drugs...

 
 
 
Scaling up the Manufacturing Process of Adoptive T Cell Immunotherapy

SCALING UP THE MANUFACTURING PROCESS OF ADOPTIVE T CELL IMMUNOTHERAPY

Standardizing the manufacturing process is of the ultimate importance for scaling up Adoptive Cell Therapy , where closed system, automation,...

Failed Clinical Trial Puts Eli Lilly Cancer Drug in Limbo

FAILED CLINICAL TRIAL PUTS ELI LILLY CANCER DRUG IN LIMBO

An Eli Lilly drug on the market for a rare form of cancer is now in limbo, after it failed a trial needed to retain the FDA approval...

 
 
 
 
 
 
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

BIO ROUNDUP: $74B FOR CELGENE, TWO CAR-T TALES, READY FOR SF & MORE

In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy,...